Literature DB >> 9502409

Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis.

P T Nooijen1, J R Westphal, A M Eggermont, C Schalkwijk, R Max, R M de Waal, D J Ruiter.   

Abstract

Some malignant tumors induce a cellular immune response that results in the formation of an inflammatory infiltrate and subsequent tumor regression. The infiltrating leukocytes extravasate from the bloodstream after binding to adhesion receptors on the surface of the endothelium. One of these receptors is the P-selectin molecule (CD62P) that is constitutively present on normal capillaries. We observed that P-selectin expression is absent from the microvasculature in advanced primary melanoma and in melanoma metastasis in contrast to benign melanocytic lesions where P-selectin expression was identical to that in normal skin. We suggest that one of the mechanisms by which advanced melanoma lesions evade inflammatory regression operates via a decrease of endothelial P-selectin expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502409      PMCID: PMC1858387     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

Review 1.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance.

Authors:  S Ferrone; F M Marincola
Journal:  Immunol Today       Date:  1995-10

2.  Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors.

Authors:  A W Griffioen; C A Damen; S Martinotti; G H Blijham; G Groenewegen
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

3.  In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury.

Authors:  A S Weyrich; X Y Ma; D J Lefer; K H Albertine; A M Lefer
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

4.  Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage.

Authors:  D Schadendorf; S Diehl; T Zuberbier; C Schadendorf; B M Henz
Journal:  Dermatology       Date:  1996       Impact factor: 5.366

5.  Increased PMN adherence on endothelial cells after hypoxia: involvement of PAF, CD18/CD11b, and ICAM-1.

Authors:  T Arnould; C Michiels; J Remacle
Journal:  Am J Physiol       Date:  1993-05

6.  Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation.

Authors:  D J Pinsky; Y Naka; H Liao; M C Oz; D D Wagner; T N Mayadas; R C Johnson; R O Hynes; M Heath; C A Lawson; D M Stern
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

7.  Vascular endothelial platelet endothelial adhesion molecule-1 (PECAM-1) expression is decreased by TNF-alpha and IFN-gamma. Evidence for cytokine-induced destabilization of messenger ribonucleic acid transcripts in bovine endothelial cells.

Authors:  R J Stewart; T S Kashour; P A Marsden
Journal:  J Immunol       Date:  1996-02-01       Impact factor: 5.422

8.  Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels.

Authors:  D Schadendorf; J Heidel; C Gawlik; L Suter; B M Czarnetzki
Journal:  J Natl Cancer Inst       Date:  1995-03-01       Impact factor: 13.506

9.  Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6.

Authors:  S F Yan; I Tritto; D Pinsky; H Liao; J Huang; G Fuller; J Brett; L May; D Stern
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

10.  Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma.

Authors:  L Piali; A Fichtel; H J Terpe; B A Imhof; R H Gisler
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Tissue-specific homing of immune cells in malignant skin tumors.

Authors:  Hajnalka Jókai; Márta Marschalkó; Judit Csomor; József Szakonyi; Orsolya Kontár; Gábor Barna; Sarolta Kárpáti; Péter Holló
Journal:  Pathol Oncol Res       Date:  2012-04-24       Impact factor: 3.201

Review 2.  Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.

Authors:  Fabrizio Marcucci; Matteo Bellone; Cristiano Rumio; Angelo Corti
Journal:  MAbs       Date:  2012-12-04       Impact factor: 5.857

3.  Serum levels of the soluble adhesion molecules in patients with malignant melanoma.

Authors:  V Yasasever; F Tas; D Duranyildiz; H Camlica; S Kurul; N Dalay
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 4.  Are selectins involved in metastasis?

Authors:  T Krause; G A Turner
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

Review 5.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.

Authors:  A M Eggermont; T L ten Hagen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 6.  Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies.

Authors:  Daniela Gm Tantalo; Amanda J Oliver; Bianca von Scheidt; Aaron J Harrison; Scott N Mueller; Michael H Kershaw; Clare Y Slaney
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

Review 7.  The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.

Authors:  G A Hospers; E A Eisenhauer; E G de Vries
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

Review 8.  A Task Force Against Local Inflammation and Cancer: Lymphocyte Trafficking to and Within the Skin.

Authors:  Fanny Lafouresse; Joanna R Groom
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

Review 9.  Anti-angiogenesis: making the tumor vulnerable to the immune system.

Authors:  Arjan W Griffioen
Journal:  Cancer Immunol Immunother       Date:  2008-04-26       Impact factor: 6.968

Review 10.  Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?

Authors:  Lih Yin Tan; Carmela Martini; Zvi G Fridlender; Claudine S Bonder; Michael P Brown; Lisa M Ebert
Journal:  Clin Transl Immunology       Date:  2017-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.